Histopathology of Myelodysplastic Syndromes: The FAB Classification (Proposals) Applied to Bone Marrow Biopsy

1987 ◽  
Vol 87 (2) ◽  
pp. 180-186 ◽  
Author(s):  
Francoise Delacrétaz ◽  
Pierre-Michel Schmidt ◽  
Dominique Piguet ◽  
Fedor Bachmann ◽  
Jose Costa
2013 ◽  
Vol 2 (3) ◽  
pp. 219-228
Author(s):  
Emanuela Boveri ◽  
Giorgio Croci ◽  
Umberto Gianelli ◽  
Marcello Gambacorta ◽  
Giuseppe Isimbaldi ◽  
...  

1992 ◽  
pp. 67-73 ◽  
Author(s):  
G. Lambertenghi-Deliliers ◽  
D. Soligo ◽  
C. Annaloro ◽  
E. Pozzoli ◽  
A. Riva

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2518-2518
Author(s):  
ZiYi Lim ◽  
Sally Killick ◽  
Jamie Cavenagh ◽  
David Bowen ◽  
Dominic Culligan ◽  
...  

Abstract In patients with myelodysplastic syndromes (MDS), there is increasing evidence to suggest that immunological dysregulation plays an important role contributing to ineffective haematopoiesis and progressive cytopenias. Several studies have suggested that a sub-group of patients with low-risk MDS may respond to treatment with anti-thymocyte globulin (ATG). The characteristics of this group are still being defined. We reviewed the outcomes of 68 patients with MDS treated with ATG in the United Kingdom and Italy. All patients received a single treatment course of lymphoglobuline (Sangstat-Genzyme) (1.5 vials/10 kg/day for 5 days;1 vial contains 100mg protein). The study end-point was response at 6 months. Haematological response was assessed as per the Cheson criteria. The median age of the patients was 51.5 years (range: 19–75). There were 40 (59%) male and 28 (41%) female patients. The diagnosis as defined by FAB classification was refractory anaemia (RA) n=53, refractory anaemia with ring sideroblasts (RARS) n=4, and refractory anaemia with excess blasts (RAEB) n=11. IPSS was low n=3, Int-1 n=53, Int-2 n=5, high n=4. 19/54 patients had a normocellular/hypercellular bone marrow, 35/54 patients had a hypocellular bone marrow. Cytogenetic risk as defined by IPSS was low n=50, intermediate n=8, high n=6. HLA-DR15 was available in 27 patients, of which 10 were positive. Only 1 of 23 patients tested for the presence of PNH clone was positive. 61/68 patients were blood transfusion dependent and 31/68 were platelet transfusion dependent at time of treatment. The median duration from diagnosis to treatment with ATG was 13 months (range: 0.5–342). 30/68 (43%) patients had a partial or complete response to ATG. The median age of responders was 49.5 years (range: 19–73). At 6 months assessment, 26/30 patients had a erythroid response (20 major, 6 minor), 10/30 patients had a neutrophil response (8 major, 2 minor) and 20/30 patients had a platelet response (12 major, 8 minor). The median duration of response was 29 months (range: 2–83). 6/30 (20%) patients (3 RAEB, 3 RA) relapsed after initial response to ATG with 3 patients progressing to AML (2 RAEB, 1 RA). There was no significant difference in age, time from diagnosis to treatment, bone marrow cellularity, FAB classificiation, cytogenetic risk or HLA-DR15 status between responders and non-responders. However, responders to ATG had a more favourable IPSS (Low, Int-1 as compared to Int-2, High) (p=0.03). The 3 year actuarial overall survival between responders and non-responders is 87% vs 40% (p=0.01). On univariate analysis, response to ATG, IPSS, and FAB classification were strongly associated with overall survival, however on multivariate analysis, IPSS was the only independent variable for overall survival (p<0.01 HR 3.46 95%CI 2.01–5.94). A single course of ATG can induce durable haematological responses in a significant proportion of patients with MDS, with improved overall survival. ATG should be considered as a treatment option in patients with low IPSS.


1989 ◽  
Vol 13 (9) ◽  
pp. 833-839 ◽  
Author(s):  
D.G. Oscier ◽  
A. Worsley ◽  
S. Darlow ◽  
A. Figes ◽  
J.D. Williams ◽  
...  

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4916-4916
Author(s):  
Masaaki Takatoku ◽  
Toshihiko Sato ◽  
Kaoru Hatano ◽  
Ken Omine ◽  
Masaki Mori ◽  
...  

Abstract Myelodysplastic syndromes (MDS) and aplastic anemia (AA) are classified bone marrow failure syndromes. Their clinical and pathological features partly overlap. It is sometimes difficult to distinguish hypoplastic MDS from AA by using current common diagnostic methods such as bone marrow biopsy and chromosome analysis. Although magnetic resonance image (MRI) is useful for diagnosis of MDS with hypercellular bone marrow, it is difficult to discriminate between hypoplastic MDS and AA using this method because the high intensity patterns on T1-enhanced images are similar in these disorders. Quantitative imaging with fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) has been recognized as a useful examination for discrimination between benign and malignant regions in various conditions. Since the decrease in FDG uptake at the late phase is much slower in a malignant region than in a benign region, dual time point imaging provides more accurate information than does conventional single time point scanning. In this study, we investigated the usefulness of dual time protocol FDG-PET in differential diagnosis of hypoplastic MDS and AA. Seventeen patients (7 with typical MDS (RA), 4 with hypoplastic MDS, 6 with AA) and 30 healthy adults agreed to participate in this study. Bone marrow biopsy, FDG-PET, MRI and CT were carried out. Spine, femur and iliac lesions were detected by their increased FDG uptake at 60 and 120 min after injection of 0.12 mCi/kg of FDG. The mean lesional standardized uptake values (SUVmean) at 60 and 120 min after injection of FDG were determined. While the median SUVmean of normal lumbar regions at 60 min was 1.123 ± 0.219, that of MDS cases was 2.06 (range, 1.62–2.32). At 120 min, the median SUVmean of normal cases was 1.180 ± 0.119, whereas that of MDS cases was 2.44 (range, 2.08–2.98). It is noteworthy that the SUVmean of four hypoplastic MDS cases was also high (ranges: 1.96–2.23 at 60 min and 1.97–2.52 at 120 min), suggesting that bone marrow in hypoplastic MDS has a hyper-metabolic state of glucose like other malignant disorders. We also observed a patchy hot area, which may be a visualization of ineffective hematopoiesis, throughout the spine image of hypoplastic MDS. In contrast, the SUVmeans at both time points of four AA cases were not different from those in normal control cases. These results suggest that functional imaging analysis using an FDG-PET dual time protocol enables discrimination between hypoplastic MDS and AA, in which MR images similar intensities.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4841-4841
Author(s):  
Silvia M.M. Magalhães ◽  
Rosane Bittencourt ◽  
Elvira Velloso ◽  
Maria de Lourdes Chauffaille ◽  
Alita Andrade Azevedo ◽  
...  

Abstract Abstract 4841 Myelodysplastic syndromes (MDS) are a group of acquired clonal stem cell disorders that mainly affect the elderly population, characterized by ineffective hematopoiesis and high risk of leukemic transformation. MDS are heterogeneous in terms of morphology, clinical features and survival. An increasing body of work reveals that there might be differences in clinical features between Asian and Western cases. Japanese patients seem to be younger, have a lower frequency of refractory anemia (RA) with ringed sideroblast (RARS) and a higher frequency of RA, according to FAB classification, as well as different prognostic factors such as the frequency of cytogenetic abnormalities. Incidence rates for MDS in Brazil are unavailable. The purpose of the study was to obtain epidemiological data of MDS adult patients who presented from January 2003 to December 2007 in 10 Brazilian tertiary-care hematology centers from different regions of the country. Patient data collected by participating physicians were entered and stored with the use of an internet-based, data collection tool. Blood counts, bone marrow aspiration, trephine biopsy and chromosomal study were recorded. Survival was estimated through Kaplan-Meier method and the difference between survival curves was assessed by means of Log-Rank Test. Death incidence rates were estimated and compared. Statistical analyses of relevant variables were performed. Three hundred and forty three patients with diagnosis of MDS according to FAB/WHO classification were included in this retrospective analysis. The mean age at presentation was 68 years (range 17 to 98). Fifty percent of cases were male. Cigarette smoking, alcohol abuse and pesticide/herbicide exposure were reported in 33.5%, 13.4% and 14.3% respectively. Median hemoglobin was 8.7 g/dL, median neutrophils count was 1,575/mm3 and median platelets count was 97,000/mm3. There was no excess of blasts in 68.4% of cases. Bone marrow biopsy was performed in 78.5% of patients. Lymphoid nodules were seen in 11.3% and any degree of fibrosis in 28.6%. Cytogenetic analysis was performed in 67.8% of cases and showed chromosomal abnormalities in 50.5%. The del(5q) isolated or combined with other alterations were observed in 6.0%. Flow cytometry analysis for CD55 and CD59 was performed in 11,3% and was normal in 97,4%. Near 8% of cases were classified as secondary MDS. The distribution of disease subtypes according to FAB classification was: RA 42,3%, RARS 9,0%, RA with excess of blasts (RAEB) 20,7%, RAEB-t 4,2% and chronic myelomonocytic leukemia (CMML) 3,9%. According to IPSS patients were stratified as low-risk (low risk plus intermediate I) 55,9% and high risk (intermediate II and high risk) 13,1%. In 30,1% no stratification was possible. In 26,5% of cases iron overload was diagnosed although only 28,3% of cases had performed serum ferritin. The follow-up time ranged from 1 to 78 months (mean: 28 months). Thirty-six percent of patients died and the death was MDS-related in 68.3% of cases. The high and low risk survival curves were significantly different (p<0,001), and, the death incidence rate (per 1000 person.month) was 8,7 (95% CI: 6,6-11,4) and 29,1 (95% CI: 19,5-43,4) for the low and high-risk group respectively. This clinical registry of adult Brazilian MDS patients represents a unique opportunity to gain insight about these disorders and its demographic and clinical features and provide an important baseline for future studies. Disclosures No relevant conflicts of interest to declare.


2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Jacob D. Kjelland ◽  
Denis M. Dwyre ◽  
Brian A. Jonas

Acquired elliptocytosis is a known but rarely described abnormality in the myelodysplastic syndromes (MDS). Here we report the case of an elderly male who was admitted to the hospital with chest pain, dyspnea, and fatigue and was found to be anemic with an elliptocytosis that had only recently been noted on peripheral smears of his blood. After bone marrow biopsy he was diagnosed with MDS with ring sideroblasts and multilineage dysplasia and acquired elliptocytosis. Here we report a rare case of acquired elliptocytosis cooccurring with MDS with ring sideroblasts and multilineage dysplasia.


1993 ◽  
Vol 66 (2) ◽  
pp. 85-91 ◽  
Author(s):  
G. Lambertenghi-Deliliers ◽  
C. Annaloro ◽  
A. Oriani ◽  
D. Soligo ◽  
E. Pozzoli ◽  
...  

2017 ◽  
Vol 55 ◽  
pp. S78
Author(s):  
H.S. Oster ◽  
G. Carmi ◽  
A. Kolomansky ◽  
E. Joffe ◽  
I. Kaye ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document